| Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation H Gelderblom, J Verweij, K Nooter, A Sparreboom European journal of cancer 37 (13), 1590-1598, 2001 | 2135 | 2001 |
| Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine A Sparreboom, J Van Asperen, U Mayer, AH Schinkel, JW Smit, ... Proceedings of the National Academy of Sciences 94 (5), 2031-2035, 1997 | 1122 | 1997 |
| Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) RHJ Mathijssen, RJ van Alphen, J Verweij, WJ Loos, K Nooter, G Stoter, ... Clinical cancer research 7 (8), 2182-2194, 2001 | 934 | 2001 |
| Pharmacological effects of formulation vehicles: implications for cancer chemotherapy AJ Ten Tije, J Verweij, WJ Loos, A Sparreboom Clinical pharmacokinetics 42, 665-685, 2003 | 807 | 2003 |
| Herbal remedies in the United States: potential adverse interactions with anticancer agents A Sparreboom, MC Cox, MR Acharya, WD Figg Journal of clinical oncology 22 (12), 2489-2503, 2004 | 639 | 2004 |
| Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline JJ Griggs, PB Mangu, H Anderson, EP Balaban, JJ Dignam, WM Hryniuk, ... Journal of clinical oncology 30 (13), 1553-1561, 2012 | 591 | 2012 |
| Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol) A Sparreboom, CD Scripture, V Trieu, PJ Williams, T De, A Yang, B Beals, ... Clinical cancer research 11 (11), 4136-4143, 2005 | 590 | 2005 |
| Effects of St. John's wort on irinotecan metabolism RHJ Mathijssen, J Verweij, P De Bruijn, WJ Loos, A Sparreboom Journal of the National Cancer Institute 94 (16), 1247-1249, 2002 | 579 | 2002 |
| Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma QC Ryan, D Headlee, M Acharya, A Sparreboom, JB Trepel, J Ye, ... Journal of Clinical Oncology 23 (17), 3912-3922, 2005 | 494 | 2005 |
| Contribution of organic cation transporter 2 (OCT2) to cisplatin‐induced nephrotoxicity KK Filipski, RH Mathijssen, TS Mikkelsen, AH Schinkel, A Sparreboom Clinical Pharmacology & Therapeutics 86 (4), 396-402, 2009 | 478 | 2009 |
| Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications A Sparreboom, L Van Zuylen, E Brouwer, WJ Loos, P De Bruijn, ... Cancer research 59 (7), 1454-1457, 1999 | 438 | 1999 |
| Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects LR Treviño, N Shimasaki, W Yang, JC Panetta, C Cheng, D Pei, D Chan, ... Journal of Clinical Oncology 27 (35), 5972-5978, 2009 | 391 | 2009 |
| Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL A Sparreboom, O van Tellingen, WJ Nooijen, JH Beijnen Cancer research 56 (9), 2112-2115, 1996 | 389 | 1996 |
| Role of formulation vehicles in taxane pharmacology L Van Zuylen, J Verweij, A Sparreboom Investigational new drugs 19, 125-141, 2001 | 383 | 2001 |
| Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias I Gojo, A Jiemjit, JB Trepel, A Sparreboom, WD Figg, S Rollins, ML Tidwell, ... Blood 109 (7), 2781-2790, 2007 | 368 | 2007 |
| Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives CD Scripture, WD Figg, A Sparreboom Current neuropharmacology 4 (2), 165-172, 2006 | 352 | 2006 |
| Irinotecan pathway genotype analysis to predict pharmacokinetics RHJ Mathijssen, S Marsh, MO Karlsson, R Xie, SD Baker, J Verweij, ... Clinical cancer research 9 (9), 3246-3253, 2003 | 325 | 2003 |
| Role of body surface area in dosing of investigational anticancer agents in adults, 1991–2001 SD Baker, J Verweij, EK Rowinsky, RC Donehower, JHM Schellens, ... Journal of the National Cancer Institute 94 (24), 1883-1888, 2002 | 324 | 2002 |
| Pharmacogenomics of ABC transporters and its role in cancer chemotherapy A Sparreboom, R Danesi, Y Ando, J Chan, WD Figg Drug Resistance Updates 6 (2), 71-84, 2003 | 312 | 2003 |
| Rational development of histone deacetylase inhibitors as anticancer agents: a review MR Acharya, A Sparreboom, J Venitz, WD Figg Molecular pharmacology 68 (4), 917-932, 2005 | 303 | 2005 |
Sharyn BakerThe Ohio State University在 osu.edu 的电子邮件经过验证
